1
|
Giannoudis A, Varešlija D, Sharma V, Zakaria R, Platt-Higgins A, Rudland P, Jenkinson M, Young L, Palmieri C. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO Open 2022; 7:100636. [PMID: 36423363 PMCID: PMC9808462 DOI: 10.1016/j.esmoop.2022.100636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/11/2022] [Accepted: 10/15/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Immune checkpoint inhibition is an established treatment in programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative (TN) breast cancer (BC). However, the immune landscape of breast cancer brain metastasis (BCBM) remains poorly defined. MATERIALS AND METHODS The tumour-infiltrating lymphocytes (TILs) and the messenger RNA (mRNA) levels of 770 immune-related genes (NanoString™, nCounter™ Immuno-oncology IO360) were assessed in primary BCs and BCBMs. The prognostic role of ARG2 transcripts and protein expression in primary BCs and its association with outcome was determined. RESULTS There was a significant reduction of TILs in the BCBMs in comparison to primary BCs. 11.5% of BCs presented a high immune infiltrate (hot), 46.2% were altered (immunosuppressed/excluded) and 34.6% were cold (no/low immune infiltrate). 3.8% of BCBMs were hot, 23.1% altered and 73.1% cold. One hundred and twelve immune-related genes including PD-L1 and CTLA4 were decreased in BCBM compared to the primary BCs (false discovery rate <0.01, log2 fold-change >1.5). These genes are involved in matrix remodelling and metastasis, cytokine-chemokine signalling, lymphoid compartment, antigen presentation and immune cell adhesion and migration. Immuno-modulators such as PD-L1 (CD274), CTLA4, TIGIT and CD276 (B7H3) were decreased in BCBMs. However, PD-L1 and CTLA4 expression was significantly higher in TN BCBMs (P = 0.01), with CTLA4 expression also high in human epidermal growth factor receptor 2-positive (P < 0.01) compared to estrogen receptor-positive BCBMs. ARG2 was one of four genes up-regulated in BCBMs. High ARG2 mRNA expression in primary BCs was associated with worse distant metastasis-free survival (P = 0.038), while ARG2 protein expression was associated with worse breast-brain metastasis-free (P = 0.027) and overall survival (P = 0.019). High transcript levels of ARG2 correlated to low levels of cytotoxic and T cells in both BC and BCBM (P < 0.01). CONCLUSION This study highlights the immunological differences between primary BCs and BCBMs and the potential importance of ARG2 expression in T-cell depletion and clinical outcome.
Collapse
Affiliation(s)
- A. Giannoudis
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - D. Varešlija
- The School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - V. Sharma
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK,Department of Pathology, Royal Liverpool University Hospital NHS Trust, Liverpool, UK
| | - R. Zakaria
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - A. Platt-Higgins
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - P.S. Rudland
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - M.D. Jenkinson
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - L.S. Young
- Endocrine Oncology Research Group, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - C. Palmieri
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK,The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,Correspondence to: Prof. Carlo Palmieri, University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. Tel: +44 151 7949813 @cancermedic
| |
Collapse
|
2
|
Giannoudis A, Vareslija D, Sharma V, Zakaria R, Platt-Higgins A, Rudland P, Jenkinson M, Young L, Palmieri C. 20P The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
3
|
Giannoudis A, Clarke K, Zakaria R, Vareslija D, Farahani M, Rainbow L, Platt-Higgins A, Ruthven S, Brougham K, Rudland PS, Jenkinson MD, Young L, Falciani F, Palmieri C. Abstract P6-05-02: Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite sequential improvements in the adjuvant treatment of breast cancer (BC), recurrence and metastasis remains a major clinical problem and in particular, brain metastasis (BCBM). A number of microRNAs (miRNAs) have been linked to the metastatic process in BC, but to date there is limited work on the microRNAs involved in BCBM. The current study aim to identify differentially expressed miRNAs within primary breast cancer who did not recur (BCNR) versus primary BC cases which did recur (BCR) and their matched BCBM cases.
Methods: Formalin-fixed paraffin-embedded (FFPE) material was collected of 12 primary BCNRs from the Liverpool tissue bank and of 40 paired primary BCR samples and their matched BCBM from the Walton Research Tissue Bank and RCSI National Breast Cancer Bioresource. miRNA was extracted (Qiagen miRNeasy FFPE kit) and profiled using the NanoString™ nCounter™ miRNA Expression Assay (Human v3 miRNA). The differentially expressed miRNAs between BCNR versus BCR and BCR versus their matched BCBM were identified by significance of microarray analysis (SAM) on the MeV4.9 software. Pathway analysis was performed using the DIANA-mirPath v3.0 software and the Ingenuity Pathway Analysis (IPA) to identify a network of genes/pathways regulated by the differentially expressed miRNAs.
Results: 12 BCNR and 30 matched pairs of BCR and BCBM passed the quality control and normalisation processes. Principal component analysis (PCA) performed on 166 miRNAs after QC/normalisation clearly distinguishes the BCNR and the primary BCR from the matched BCBM cases, whereas SAM revealed 58 differentially expressed miRNAs with a 10% FDR (false discovery rate) and an absolute log2 fold-change (FC) >1 between BCNR and BCR and 11 between the matched BCs and BCBMs. Pathway clustering revealed that these differentially expressed miRNAs (10% FDR, log2FC>1) within both BCNR vs BCR and BCR vs BCBM cohorts are highly enriched for genes involved in extracellular matrix (ECM)-receptor interactions, proteoglycans, adherens junctions, TGF-β, p53 and Hippo signalling. IPA identified a network of genes, implicated in the processes of breast cancer invasion and metastasis, regulated by the identified miRNAs, such as, TWIST, MET, TP53, MYC, EZH2, ZEB1, TAGLN and BIRC5. Four of the significantly differentially expressed miRNAs, hsa-miR-132-3p, hsa-miR-199a-5p, hsa-miR-150-5p and hsa-miR-155-5p were present within both cohorts (BCNR vs BCR and BCR vs BCBM) and regulate genes involved in Hippo and TGF-β signalling (DIANA-mirPath v3.0 analysis: p=5.23x10-08 and p=2.67x10-07 respectively).
Conclusion: The current study, utilising a large cohort of paired BCR and BCBM cases, provides novel insight into the molecular mechanisms and role of miRNAs in BCBM. Four miRNAs (hsa-miR-132-3p, hsa-miR-199a-5p, hsa-miR-150-5p and hsa-miR-155-5p) in particular could be potentially used to identify patients with increased risk of developing brain metastasis and help facilitate the development of specific treatments for BCBM, which to date have proved elusive. The miRNAs identified require further exploration as potential biomarkers as well as novel therapeutic targets.
Citation Format: Giannoudis A, Clarke K, Zakaria R, Vareslija D, Farahani M, Rainbow L, Platt-Higgins A, Ruthven S, Brougham K, Rudland PS, Jenkinson MD, Young L, Falciani F, Palmieri C. Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Giannoudis
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - K Clarke
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - R Zakaria
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - D Vareslija
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - M Farahani
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - L Rainbow
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - A Platt-Higgins
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - S Ruthven
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - K Brougham
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - PS Rudland
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - MD Jenkinson
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - L Young
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - F Falciani
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| | - C Palmieri
- University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom; University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; RCSI Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Royal Liverpool University Hospital, Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Bebington, Wirral, United Kingdom
| |
Collapse
|
4
|
Giannoudis A, Zakaria R, Platt-Higgins A, Syed KAR, Ashton K, Dawson T, Rudland PS, Holcombe C, Jenkinson MD, Palmieri C. Abstract P2-03-04: Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-03-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION:
c-MET amplification/overexpression has been associated with treatment failure and progression in many cancers, including breast cancer (BC). c-MET showed amplification by fluorescent in situ hybridization (FISH) in 27% of trastuzumab-treated HER2-positive patients. These patients had a high trastuzumab failure rate and a shorter time to progression. Up to 50% of patients with metastatic HER2-positive disease will develop brain metastases (BM) during their disease course and in approximately one third, brain is the first site of progression. Amplification/copy number variations (CNVs) are mainly assessed by FISH whereas overexpression is assessed by immunohistochemistry (IHC). We present a PCR-based assay (digital-PCR) able to determine CNV in c-MET and HER2 in a cohort of patients with metastatic BC to the brain and demonstrate the correlation of CNV to protein expression.
METHODS:
DNA was isolated from paraffin-embedded tissues of 23 paired primary BC-BM cases. CNV was analysed by the QuantStudioTM 3D-Digital-PCR (QS3D) and real-time qPCR (both from ThermoFisher Scientific). The breast MCF7, T47D, BT474, AU565, SKBR3 and the gastric MKN45 cell lines were used as controls for the HER2 and c-MET CNV assays. Copy number per diploid genome was calculated using the absolute quantification number of FAM-labelled target and VIC-labelled RNaseP reference multiplied by 2. Cases with ≤2 copies are classified as normal whereas cases with >2 were classified as amplified. The HER2 positivity of the primary BC cases was routinely assessed by IHC. The c-MET protein expression was assessed by IHC using the c-MET(3D4) monoclonal antibody (ThermoFisher Scientific).
RESULTS:
CNV in c-MET by QS3D digital-PCR was detected in 69.6% of primary BC (ER-/HER2+:2, ER+/HER2+:5, ER+/HER2-:8, Triple-negatives:5, unknown:3) as well as 69.6% of BM, whereas HER2 CNV was observed in 39.1% primary BC and 52.2% BM. In the HER2-positive cases, the prevalence of HER2 CNV was 100% in both primary BC and BM. Within these cases, c-MET CNV was 85.7% in the primary BC and 71.43% in BM. CNVs in both genes were observed in 30.4 % of all primary and 39.1% of BM. The CNV data are presented in Table 1.
CNV data for c-MET and HER2 between primary breast cancer (BC) and corresponding brain metastatic (BM) casesc-MET CNVHER2 CNVBCBMBCBM>2: 16>2: 12≤2: 4>2: 9>2: 8≤2: 1≤2: 7>2: 4≤2: 3≤2: 14>2: 4≤2: 10
There was a high concordance between the QS3D and qPCR data with Pearson's R=0.74 (p<0.00001).
A significant correlation between HER2 protein expression and CNV was observed (Fisher's exact test p=0.0005). Data will be presented on c-MET protein expression in the pair samples.
CONCLUSIONS:
The prevalence of CNV is much higher than that reported by immunohistochemistry and FISH in the literature to date, possibly due to the sensitivity of the digital-PCR technology. The high level of c-MET CNV in primary and metastatic BC, and the concurrent CNV in both genes warrants further investigation. It also highlights the potential to use c-MET directed therapy particularly in HER2+ BC and reinforces the potential importance of precise detection methods in both the primary and metastatic setting. Analysis of a larger series is currently on-going.
Citation Format: Giannoudis A, Zakaria R, Platt-Higgins A, Syed KAR, Ashton K, Dawson T, Rudland PS, Holcombe C, Jenkinson MD, Palmieri C. Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-04.
Collapse
Affiliation(s)
- A Giannoudis
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - R Zakaria
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - A Platt-Higgins
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - KAR Syed
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - K Ashton
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - T Dawson
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - PS Rudland
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - C Holcombe
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - MD Jenkinson
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| | - C Palmieri
- University of Liverpool, ITM, Liverpool, Merseyside, United Kingdom; University of Liverpool, The Walton Centre, Liverpool, Merseyside, United Kingdom; University of Liverpool, IIB, Liverpool, Merseyside, United Kingdom; Royal Preston Hospital, Fulwood, Preston, Lancashire, United Kingdom; The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
| |
Collapse
|
5
|
Palmieri C, Rudraraju B, Giannoudis A, Moore D, Shaw J, Chan S, Ellis IO, Caldas C, Coombes RC, Carroll JS, Ali S, Abdel-Fatah TMA. Abstract P5-08-17: A study of c-Jun N-terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-08-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The AP-1 transcription factor c-Jun is a key downstream target of c-Jun N-terminal kinase (JNK) which mediates intracellular signalling associated with a variety of cellular functions. The JNK pathway in breast cancer (BC) can be attenuated via loss of function mutations in MAPK kinases as well as via PIK3CA mutations; however, there is contradictory information about the role of JNK pathway and its clinical implications in BC.
Methods
In the current study, the clinicopathological implications of JNK and JUN mRNA expressions were evaluated in multiple independent BC datasets: a) Training-set (Uppsala cohort; n=249), b) Test-set (human genome atlas database; n=540), c) External validation-set (METABRIC cohort; n=1952) and d) Multicentre pooled databases (n=5530). The clinicopathological associations of their phosphorylated proteins (p-Jnk and p-c-Jun) were assessed in the Nottingham Tenovus Primary BC Series (n= 1650) and in an ER negative cohort (n=450).
Results
Both JNK and c-JUN mRNA high expressions were significantly associated with PAM50-Luminal A and ER+/HER2-/low proliferation molecular BC subtypes, tubular/lobular types, and integrative molecular clusters 4 (IntClust.4), ps<0.001. Whereas BC that had both low JNK and c-JUN mRNA, were significantly associated with large tumour size, high grade, absence of hormonal receptors (HR), HER2 overexpression, PAM50 HER2 and PAM50 Basal molecular subtypes, and IntClust.1, 9 and 10 BCs; ps<0.001.
There was a significant positive correlations between p-Jnk and p-c-Jun protein levels (p<0.0001), however; our data suggested that differential p-Jnk/p-c-Jun expression may influence BC phenotypes. BC with p-Jnk-ve/p-c-Jun-ve were associated with the most aggressive phenotypes including largest tumour size, highest grade, lympho-vascular invasion, absence of HR, basal-like-phenotype, HER2 overexpression, and loss of double strand , single stand and base excision DNA repair proteins (ps<0.0001). In addition p-Jnk-ve/ pc-Jun-ve phenotype was associated with the lowest levels of p-38, ATF2, and p-ATF2; ps<0.001. Interestingly, low levels of either c-JUN-mRNA or pc-Jun protein, was associated with, PAM50-luminal B, epithelial mesenchymal transition and TP53 mutation and loss of its downstream proteins such as MDM2, MDM4, Bcle2 and p21; ps<0.05.
JNK+ (mRNA and p-Jnk) and c-JUN+ (mRNA and p-c-Jun) individually were associated with prolonged BC specific survival (ps<0.001). Multivariate cox regression models that included other validated prognostic factors and therapies revealed that c-JUN-mRNA (Uppsala: p=0.005 and METABIRIC: p=0.036) and p-c-Jun (HR: 0.69; 95% CI = 0.55-0.88; p=0.002) were independently associated with clinical outcome. Furthermore, in ER+ high risk BC, exposure to tamoxifen was associated with decreased risk of death from BC in those patients with p-c-Jun-ve BC (HR: 0.65; 95% CI: 0.45-0.95; p=0.025).
Conclusion
JNK and c-JUN mRNA as well as p-Jnk and p-c-Jun protein levels are associated with luminal BC, with p-c-Jun being found to be an independent prognostic factor. The interaction between p-Jnk, p-c-Jun and TP53 mutation could predict response to endocrine therapy in ER+ BC. The role of the transcriptionally active form of c-JUN warrants further investigation with regard to its role in BC.
Citation Format: Palmieri C, Rudraraju B, Giannoudis A, Moore D, Shaw J, Chan S, Ellis IO, Caldas C, Coombes RC, Carroll JS, Ali S, Abdel-Fatah TMA. A study of c-Jun N-terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-17.
Collapse
Affiliation(s)
- C Palmieri
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - B Rudraraju
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - A Giannoudis
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - D Moore
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - J Shaw
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - S Chan
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - IO Ellis
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - C Caldas
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - RC Coombes
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - JS Carroll
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - S Ali
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| | - TMA Abdel-Fatah
- University of Liverpool, Liverpool, United Kingdom; University of Leicester, Leicester, United Kingdom; Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Imperial College, London, United Kingdom
| |
Collapse
|
6
|
Davies A, Giannoudis A, Zhang JE, Austin G, Wang L, Holyoake TL, Müller MC, Foroni L, Kottaridis PD, Pirmohamed M, Clark RE. Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clin Pharmacol Ther 2014; 96:694-703. [PMID: 25188725 DOI: 10.1038/clpt.2014.176] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 08/13/2014] [Indexed: 01/16/2023]
Abstract
Approximately 40% of patients with chronic myeloid leukemia (CML) receiving imatinib fail treatment. There is an increased risk of CML in subjects with (i) deletions of genes encoding glutathione-S-transferase (GST)-θ1 (GSTT1) and -μ1, (GSTM1) and (ii) the GST-π1 (GSTP1) single-nucleotide polymorphism (SNP) Ile105Val (GSTP1*B; rs1695); however, their effects on imatinib treatment outcome are not known. Here, we assess the role of these GSTs in relation to imatinib treatment outcome in 193 CML patients. Deletion of GSTT1 alone, or in combination with deletion of the GSTM1 gene, significantly increased the likelihood of imatinib failure (P = 0.021 and P < 0.001, respectively). The GSTP1*B SNP was not associated with time to imatinib failure. Losses of the GSTT1 and GSTM1 genes are therefore important determinants of imatinib failure in CML. Screening for GSTT1 and GSTM1 gene deletions during diagnosis may identify patients who may be better treated using an alternative therapy.
Collapse
Affiliation(s)
- A Davies
- Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - A Giannoudis
- Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - J E Zhang
- The Wolfson Centre for Personalised Medicine, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - G Austin
- Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - L Wang
- Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - T L Holyoake
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - M C Müller
- Faculty of Medicine, University of Heidelberg, Mannheim, Germany
| | - L Foroni
- Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK
| | | | - M Pirmohamed
- The Wolfson Centre for Personalised Medicine, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - R E Clark
- Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| |
Collapse
|
7
|
Ergazaki M, Xinarianos G, Giannoudis A, Koffa M, Liloglou T, Kattamis C, Spandidos D. Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia. Oncol Rep 2012; 1:813-6. [PMID: 21607447 DOI: 10.3892/or.1.4.813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Infections caused by Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are common in multiple transfused patients, such as patients with beta-thalassaemia. The ability of the Polymerase Chain Reaction (PCR) to amplify HCMV and EBV DNA from blood and other samples makes this technique a valuable diagnostic tool for the detection of both viruses in the early stages of the infection. PCR was used for the amplification of a 435 bp region of the immediate early-1 (IE-1) gene of HCMV and a 375 bp sequence from the EcoRI B fragment of EBV genome. Blood samples from 80 patients with beta-thalassaemia were examined. HCMV was found in 14 and EBV in 12 patients. The results obtained confirm the implications of HCMV and EBV in the diagnosis of viral infections in multiple transfused patients as well as the importance of PCR technique as a valuable diagnostic tool.
Collapse
Affiliation(s)
- M Ergazaki
- NATL HELLEN RES FND,INST BIOL RES & BIOTECHNOL,GR-11635 ATHENS,GREECE. UNIV CRETE,SCH MED,CLIN VIROL LAB,IRAKLION,GREECE. UNIV ATHENS,ST SOPHIA CHILDRENS HOSP,SCH MED,DEPT PEDIAT 1,GR-11527 ATHENS,GREECE
| | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Pterygium is a chronic disease of unknown origin and pathogenesis. It is a vision threatening disease where surgical excision is effective. We examined surgically excised symptomatic pterygia for the presence of herpesviruses such as cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein-Barr virus (EBV) DNA using the polymerase chain reaction (PCR) technique. Samples of normal conjuctival tissue from limpus at 12 or 6 hours were excised in some of the eyes treated; they were used as controls. HSV DNA was detected in 9 and CMV DNA in 8 out of the 20 examined samples. In 3 out of the 20 examined samples both HSV and CMV DNA were detected whereas EBV DNA was not found in any of the examined samples. These results suggest that HSV and CMV may contribute to the pathogenesis of pterygium.
Collapse
Affiliation(s)
- D Spandidos
- UNIV CRETE,SCH MED,CLIN VIROL LAB,IRAKLION,GREECE. UNIV CRETE,SCH MED,DEPT OPHTHALMOL,IRAKLION,GREECE
| | | | | | | | | |
Collapse
|
9
|
Muthana M, Giannoudis A, Scott S, Mistry R, Murdoch C, Coffelt S, Georgeopolous L, Hamdy F, Brown N, Maitland N. Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. Drug Discov Today 2010. [DOI: 10.1016/j.drudis.2010.09.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2007; 83:258-64. [PMID: 17568400 DOI: 10.1038/sj.clpt.6100268] [Citation(s) in RCA: 199] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Some chronic myeloid leukemia (CML) patients do not respond to imatinib, whereas others lose an initial response. To identify potential imatinib failures, we investigated the expression of imatinib uptake transporter (human organic cation transporter 1; hOCT1) and efflux transporters (ATP-binding cassette transporters ABCB1, ABCG2, and ABCC1) using real-time quantitative reverse transcription-polymerase chain reaction in 70 CML patients. Patients with high pretreatment hOCT1 expression had superior complete cytogenetic response (CCR) rates (P=0.008), progression-free and overall survival (P=0.01 and 0.004). Pretreatment ABCB1, ABCG2, and ABCC1 levels did not correlate with treatment outcome. Regression analysis demonstrated that pretreatment hOCT1 expression was the most powerful predictor of CCR achievement at 6 months (P=0.002). Imatinib uptake into a CML cell line with high hOCT1 expression was greater than into those with modest or low expression (P=0.002). The expression of hOCT1, but not efflux transporters, is important in determining the clinical response to imatinib.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 1
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters/genetics
- ATP-Binding Cassette Transporters/metabolism
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents/metabolism
- Antineoplastic Agents/therapeutic use
- Benzamides
- Cell Line, Tumor
- Disease-Free Survival
- Fusion Proteins, bcr-abl
- Gene Expression Regulation, Neoplastic
- Humans
- Imatinib Mesylate
- Leukemia, Myeloid/drug therapy
- Leukemia, Myeloid/genetics
- Leukemia, Myeloid/metabolism
- Middle Aged
- Mutation
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Octamer Transcription Factor-1/genetics
- Octamer Transcription Factor-1/metabolism
- Patient Selection
- Piperazines/metabolism
- Piperazines/therapeutic use
- Protein Kinase Inhibitors/metabolism
- Protein Kinase Inhibitors/therapeutic use
- Protein-Tyrosine Kinases/genetics
- Protein-Tyrosine Kinases/metabolism
- Pyrimidines/metabolism
- Pyrimidines/therapeutic use
- Regression Analysis
- Reverse Transcriptase Polymerase Chain Reaction
- Time Factors
- Transfection
- Treatment Outcome
Collapse
Affiliation(s)
- L Wang
- University Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
Prostate cancer is the most commonly diagnosed cancer in adult males in the Western world. It accounts for one in ten cancer cases and is the second leading cause of cancer death in men, after lung cancer. A number of curative treatments are available for patients with localized prostate cancer such as radical prostatectomy, radiotherapy, or brachytherapy. However, a proportion of these men will develop progressive disease, and some will present de novo with advanced and metastatic prostate cancer, which is amenable to palliation only with androgen-withdrawal therapy. Most of these patients will eventually develop hormone refractory disease which is incurable, and for whom gene therapy, if feasible may develop as an alternative treatment option. In this review we discuss the gene therapy vectors and strategies that are currently in use, new cell-based approaches, discuss their advantages and disadvantages, and review the potential or proven pre-clinical and clinical efficacy in prostate cancer models/patients.
Collapse
Affiliation(s)
- E J MacRae
- Tumour Targeting Group, University of Sheffield Medical School, Beech Hill Road, Sheffield, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
AIM To determine the prevalence and significance of human papillomaviral types in conjunctival pterygia. METHODS Polymerase chain reaction technology was used to identify the presence of human papillomavirus (HPV) in 10 formalin fixed paraffin embedded pterygia samples. 10 conjunctival papillomas were used as positive controls. 20 conjunctival samples, 10 with primary acquired melanosis and 10 with malignant melanoma, were used as negative controls. Sample subgroups were of equal sex, race, and age distribution to eliminate bias. All samples were further analysed (for 21 HPV types) using dot-blot hybridisation techniques. RESULTS HPV was identified in 90% of the conjunctival papillomas, 50% of the pterygia samples, but no HPV was detected in the negative control group. Two pterygia showed type 6, two type 11, and one type 16. These three HPV types were also detected in papillomas. CONCLUSION These results suggest that HPV may be involved in the pathogenesis of pterygia and that broadly the same HPV types are found in pterygia and in papillomas. Persistent conjunctival HPV may possibly play a part in the recurrence of pterygia post excision but further larger studies are required to elucidate this hypothesis.
Collapse
|
13
|
Giannoudis A, Duin M, Snijders PJ, Herrington CS. Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix. Br J Cancer 2001; 84:1058-63. [PMID: 11308254 PMCID: PMC2363853 DOI: 10.1054/bjoc.2001.1695] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Human papillomaviruses (HPV) are strongly associated with cervical intraepithelial neoplasia (CIN) and invasive cancer mainly through the action of the E6 and E7 viral proteins, transcription of which is down-regulated by the E2 protein. To test the hypothesis that HPV 16 E2 variation is important in the development of high-grade squamous neoplasia of the cervix, we carried out a cross-sectional analysis of low-grade and high-grade squamous intraepithelial lesions (SILs) for specific mutations in the HPV 16 E2 gene and for E2 gene disruption in these regions. Isolates were also analysed for the HPV 16 350T-G variant. 22 of 178 low-grade SILs and 43 of 61 high-grade SILs examined, contained HPV 16. No relationship was found between the E6 350T-G variant, or the E2 hinge region 3410C-T variant, and lesion grade. However, disruption of the regions of E2 analysed was significantly more frequent in high-grade lesions, and there was a significant association between the 3684C-A variant in the E2 DNA binding domain and high-grade histology suggesting that this variant may be important in progression to high-grade intraepithelial disease.
Collapse
Affiliation(s)
- A Giannoudis
- Department of Pathology, University of Liverpool, Royal Liverpool University Hospital, Duncan Building, Daulby Street, Liverpool, L69 3GA, UK
| | | | | | | |
Collapse
|
14
|
Abstract
Human papillomaviruses (HPVs) play a central role in the aetiology of cervical neoplasia. However, only a small proportion of cervical intraepithelial lesions infected with high-risk HPVs will progress to invasive cervical carcinoma, which indicates the involvement of additional factors. An important emerging viral factor is naturally occurring intratypic sequence variation. Such variation has been used to study the geographical spread of HPVs, but there is increasing evidence that it may be important in determining the risk of development of neoplastic disease. The collected data indicate that different HPV variants have altered biochemical and biological properties and represent an additional risk factor in the development of squamous intraepithelial lesions and invasive carcinoma of the cervix. This may be relevant not only to the biology of HPV infection and its association with squamous neoplasia, but also to the use of HPV typing in clinical practice.
Collapse
Affiliation(s)
- A Giannoudis
- Department of Pathology, Royal Liverpool University Hospital, Duncan Building, Daulby Street, Liverpool L69 3GA, UK
| | | |
Collapse
|
15
|
Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000. [PMID: 11002226 DOI: 10.1002/1097-0142(20000915)89:6<1300::aid-cncr15>3.0.co;2-u] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Basal cell tetrasomy in low grade squamous intraepithelial lesions of the cervix is associated with infection by high and intermediate risk but not low risk human papillomaviruses (HPVs). It is known that the viral E6 and E7 proteins interact with p53 and p21, respectively, altering cell cycle control and leading to chromosomal instability. In this study, p53 and p21 expression was analyzed in disomic and tetrasomic low grade squamous intraepithelial lesions infected with a wide range of HPV types. METHODS HPV identification and typing was performed using both in situ hybridization and the polymerase chain reaction followed by dot blot hybridization with specific HPV probes. Interphase cytogenetic analysis using centromeric chromosomal probes also performed was to identify numeric chromosomal abnormalities. The expression of p53 and p21 was studied by immunohistochemistry using monoclonal antibodies specific for these proteins. RESULTS Increased expression of p53 and p21 was more widespread in lesions infected with low risk than with intermediate/high risk HPV types (p53, P < 0.001; p21, P < 0.01). p53 status correlated with p21 expression when analyzed according to the distribution of expression by using 3 groups, focal, regional, and diffuse (Pearson coefficient, r = 0.47, P < 0.001). In the lesions infected with intermediate/high risk HPVs, expression of p53 was significantly decreased or completely absent in tetrasomic areas, whereas expression of p21 was similar in both disomic and tetrasomic regions. CONCLUSIONS The authors' data suggest that low, intermediate, and high risk HPVs have different effects on p53 and p21 protein expression, and that the induction of numeric chromosomal abnormalities by intermediate/high risk HPVs may be related to altered expression of p53.
Collapse
Affiliation(s)
- A Giannoudis
- University of Liverpool, Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom
| | | |
Collapse
|
16
|
Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000; 89:1300-7. [PMID: 11002226 DOI: 10.1002/1097-0142(20000915)89:6<1300::aid-cncr15>3.0.co;2-u] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Basal cell tetrasomy in low grade squamous intraepithelial lesions of the cervix is associated with infection by high and intermediate risk but not low risk human papillomaviruses (HPVs). It is known that the viral E6 and E7 proteins interact with p53 and p21, respectively, altering cell cycle control and leading to chromosomal instability. In this study, p53 and p21 expression was analyzed in disomic and tetrasomic low grade squamous intraepithelial lesions infected with a wide range of HPV types. METHODS HPV identification and typing was performed using both in situ hybridization and the polymerase chain reaction followed by dot blot hybridization with specific HPV probes. Interphase cytogenetic analysis using centromeric chromosomal probes also performed was to identify numeric chromosomal abnormalities. The expression of p53 and p21 was studied by immunohistochemistry using monoclonal antibodies specific for these proteins. RESULTS Increased expression of p53 and p21 was more widespread in lesions infected with low risk than with intermediate/high risk HPV types (p53, P < 0.001; p21, P < 0.01). p53 status correlated with p21 expression when analyzed according to the distribution of expression by using 3 groups, focal, regional, and diffuse (Pearson coefficient, r = 0.47, P < 0.001). In the lesions infected with intermediate/high risk HPVs, expression of p53 was significantly decreased or completely absent in tetrasomic areas, whereas expression of p21 was similar in both disomic and tetrasomic regions. CONCLUSIONS The authors' data suggest that low, intermediate, and high risk HPVs have different effects on p53 and p21 protein expression, and that the induction of numeric chromosomal abnormalities by intermediate/high risk HPVs may be related to altered expression of p53.
Collapse
Affiliation(s)
- A Giannoudis
- University of Liverpool, Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom
| | | |
Collapse
|
17
|
Sheard JD, Vijayanand R, Herrington CS, Giannoudis A, Shaw G. High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection. Histopathology 2000; 37:87-8. [PMID: 10931225 DOI: 10.1046/j.1365-2559.2000.00955-4.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
18
|
Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, Foukas P, Kyroudi A, Laskaris G, Herrington CS, Kittas C. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol 2000; 13:644-53. [PMID: 10874669 DOI: 10.1038/modpathol.3880113] [Citation(s) in RCA: 150] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Studies on the involvement of the human papillomavirus (HPV) in initiation and progression of oral neoplasia have generated conflicting results. The observed discrepancy is attributable mainly to the varying sensitivity of the applied methodologies and to epidemiologic factors of the examined patient groups. To evaluate the role of HPV in oral carcinogenesis, we analyzed 53 potentially neoplastic and neoplastic oral lesions consisting of 29 cases of hyperplasia, 5 cases of dysplasia, and 19 cases of squamous cell carcinomas, as well as 16 oral specimens derived from healthy individuals. A highly sensitive nested polymerase chain reaction (PCR) assay was used, along with type-specific PCR, restriction fragment length polymorphism analysis, dot blotting, and nonisotopic in situ hybridization. Nested PCR revealed the presence of HPV DNA in 48 of the 53 (91%) pathologic samples analyzed, whereas none (0%) of the normal specimens was found to be infected. Positivity for HPV was independent of histology and the smoking habits of the analyzed group of patients. At least one "high risk" type, such as HPV 16, 18, and 33, was detected by type-specific PCR in 47 (98%) infected specimens, whereas only 1 (2%) squamous cell carcinoma was solely infected by a "low risk" type (HPV 6). HPV 16 was the prevailing viral type, being present in 71% of infected cases. Single HPV 16 and HPV 18 infections were confirmed by restriction fragment length polymorphism. HPV 58 was detected by dot blotting in three hyperplastic lesions. HPV positivity and genotyping were further confirmed, and the physical status of this virus was evaluated by nonisotopic in situ hybridization. Diffuse and punctate signals, indicative of the episomal and integrative pattern of HPV infection, were observed for low- and high-risk types, respectively. Our findings are suggestive of an early involvement of high-risk HPV types in oral carcinogenesis.
Collapse
Affiliation(s)
- M Bouda
- Department of Histology and Embryology, School of Medicine, University of Athens, Greece
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Giannoudis A, Evans MF, Southern SA, Herrington CS. Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific. Br J Cancer 2000; 82:424-8. [PMID: 10646899 PMCID: PMC2363287 DOI: 10.1054/bjoc.1999.0937] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Human papillomavirus (HPV) infection appears to be an early event in cervical carcinogenesis with additional abnormalities being required for biological transformation. We have analysed 179 low-grade cervical squamous intra-epithelial lesions (SILs) and 15 normal cervices for the presence of HPV using both in situ hybridization and polymerase chain reaction (PCR). PCR was performed with GP5+/GP6+ primers followed by hybridization using probes for low (HPV 6, 11, 40, 42, 43, 44), intermediate (HPV 31, 33, 35, 39, 51, 52, 58, 59, 66 and 68) and high-risk HPVs (HPV 16, 18, 45 and 56). Interphase cytogenetic analysis using pericentromeric probes for chromosomes 1, 3, 4, 6, 10, 11, 17, 18 and X was also performed to identify numerical chromosomal abnormalities. Tetrasomy of all nine chromosomes was identified within basal keratinocytes, was restricted to epithelia infected with high risk (17 of 46) or intermediate risk (23 of 83) HPVs but was not HPV type-specific. Tetrasomy was not identified in any of the epithelia infected with low risk HPVs (n = 62). These numbers include multiple infection. These findings indicate that the induction of tetrasomy is a property restricted to high and intermediate-risk HPV types but that it is not type-specific. The factors governing which lesions will develop this abnormality are as yet unclear.
Collapse
Affiliation(s)
- A Giannoudis
- University of Liverpool, Department of Pathology, Royal Liverpool University Hospital, UK
| | | | | | | |
Collapse
|
20
|
Giannoudis A, Graham DA, Southern SA, Herrington CS. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 1999; 83:66-9. [PMID: 10449610 DOI: 10.1002/(sici)1097-0215(19990924)83:1<66::aid-ijc13>3.0.co;2-k] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A polymorphism at codon 72 of the p53 gene, resulting in either an arginine or a proline residue in the protein, has been reported to affect the susceptibility of p53 to human papillomavirus (HPV) E6-mediated degradation in cultured cells. However, the relevance of this polymorphism to naturally occurring HPV infection is unclear. Therefore, we analysed its relationship to infecting HPV type and lesion grade in a series of low- and high-grade squamous intra-epithelial lesions (SILs) and invasive carcinoma of the cervix. DNA extracted from morphologically characterised, paraffin-embedded tissues (30 normal cervices, 118 low-grade SILs, 118 high-grade SILs and 43 invasive carcinomas) was examined for the presence and type of HPV DNA, and the p53 genotype was identified by both allele-specific PCR and PCR-restriction fragment length polymorphism. There was no significant relationship between the frequency of p53 genotypes and either HPV type or lesion grade. Our data do not support the hypothesis that this p53 polymorphism is involved in the development of high-grade squamous cervical disease in this population.
Collapse
Affiliation(s)
- A Giannoudis
- Department of Pathology, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
| | | | | | | |
Collapse
|
21
|
Giannoudis A, Ergazaki M, Segas J, Giotakis J, Adamopoulos G, Gorgoulis V, Spandidos DA. Detection of Epstein-Barr virus and human papillomavirus in nasopharyngeal carcinoma by the polymerase chain reaction technique. Cancer Lett 1995; 89:177-81. [PMID: 7889526 DOI: 10.1016/0304-3835(94)03667-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We used the PCR technique to detect the Epstein-Barr virus (EBV) and human papillomavirus (HPV) DNA in paraffin-embedded tissues from Greek patients with nasopharyngeal carcinoma (NPC). The oligonucleotide primers used for the detection of EBV amplify a 375-bp long sequence from the EcoRI B fragment of the viral genome, whereas for HPV the primers amplify a 151-bp long sequence of the viral genome. The PCR products were analysed by agarose gel electrophoresis and visualised by UV illumination after staining with ethidium bromide. Sixty-three specimens were examined. EBV specific sequence was amplified in 20 (32%) and HPV in 12 (19%) out of the 63 samples. There was no co-infection with EBV and HPV. Although there is a high correlation of EBV infection with poorly differentiated NPC in patients from Southern China and South-East Asia, the restricted distribution suggests genetic or environmental cofactors in the development of the neoplasm. Our results confirm this suggestion since there was only a 32% correlation of EBV with NPC in Greece. HPV may also be involved in the carcinogenesis of EBV-negative squamous cell nasopharyngeal carcinomas.
Collapse
Affiliation(s)
- A Giannoudis
- Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
| | | | | | | | | | | | | |
Collapse
|
22
|
Ergazaki M, Xinarianos G, Giannoudis A, Markomichelakis N, Tsamparlakis J, Spandidos D. Detection of hsv, CMV and ebv by the polymerase chain-reaction technique in patients with inflammatory eye-diseases. Oncol Rep 1994; 1:1207-10. [PMID: 21607517 DOI: 10.3892/or.1.6.1207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Herpes simplex virus (HSV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) have been recognized as pathogenic agents of intraocular inflammatory conditions. The ability of the Polymerase Chain Reaction (PCR) technique to amplify HSV, CMV and EBV DNA from aqueous specimens makes this technique a valuable diagnostic tool for the detection of these viral pathogens in patients with ophthalmic lesions. We used PCR for the amplification of a 476 bp long sequence from the pol I gene of HSV genome, a 435 bp region of the immediate early-1 (IE-1) gene of CMV and a 375 bp sequence from the EcoRI B fragment of EBV genome. We examined 22 aqueous humour specimens from patients with uveitis and retinitis, inflammatory eye diseases, diagnosed clinically. We found HSV in 4 (18.2%), CMV in 6 (27.3%) and EBV in 1 (4.5%) out of the 22 examined patients. None of the 22 examined samples was found to be infected with more than one of the examined viral pathogens. These data confirm the implications of the members of Herpesvirus family in inflammatory inner eye diseases and the importance of PCR technique as a diagnostic tool in clinical virology.
Collapse
Affiliation(s)
- M Ergazaki
- NATL HELLEN RES FDN,INST BIOL RES & BIOTECHNOL,GR-11635 ATHENS,GREECE. UNIV CRETE,SCH MED,CLIN VIROL LAB,IRAKLION,GREECE. GEN HOSP ATHENS,OPHTHALMOL CLIN,ATHENS,GREECE. UNIV HOSP HERAKLION,OPHTHALMOL CLIN,IRAKLION,GREECE
| | | | | | | | | | | |
Collapse
|